Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1550 - PD-L1 expression assessment in Non-Small-Cell Lung Cancer shows stability on Ventana's XT Benchmark platform – “Harmonization study”


10 Oct 2016


Poster display


Tzahi Neuman


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


T. Neuman1, G. Vainer2

Author affiliations

  • 1 Pathology, Hadassah Ein Kerem, 91120 - Jerusalem/IL
  • 2 Pathology, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv/IL


Abstract 1550


Pembrolizumab is a monoclonal antibody against programmed cell death 1 (CD279; PD-1), recently approved by the FDA as a 2nd line therapy in NSCLC with a companion diagnostic (PD-L1 22C3, Dako). Today, the only validated IHC platform for PD-L1 detection is the Link-48 platform (Dako), which lowers the availability of the test. Ventana's benchmark XT platform is a widespread IHC platform. However, data about its reliability and reproducibility using the 22C3 antibody is lacking.


A comprehensive calibration of the 22C3 PD-L1 staining on the Benchmark XT platform (Ventana) was performed by combining the FDA-approved, pre-diluted 22C3 anti PD-L1 primary antibody (Dako) with two of Ventana's DAB detection systems, UltraView and OptiView. After receiving a comparable IHC pattern, 41 NSCLC random cases were independently evaluated by 2 expert pathologists for PD-L1 protein expression, using both platforms, defining the tumor proportion score (TPS): the percentage of tumor cells showing complete or partial membrane staining. Each case was classified as PD-L1 negative, weakly positive, or strongly positive (


Using the Dako IHC platform 8, 7 and 26 cases were stratified as PD-L1 strongly positive, weakly positive and negative cases, respectively. Using the Ventana's UltraView protocol 36/41 cases (87.8%) had the same results, including the 8 strongly positive cases. Pearson's correlation score indicate a high concordance (0.91; p value


Pembrolizumab treatment for NSCLC patients is coupled to the PD-L1 TPS by Dako. The Ventana's benchmark XT platform can also be used safely to stratify patients with the same algorithm. We provide a defined PD-L1 IHC protocol which is easy to replicate as we used commercially available pre-made reagents only.

Clinical trial identification

Irrelevant. This is not a clinical trial.

Legal entity responsible for the study

Hadassah Medical Center, Jeruslaem, Isreal. Tel Aviv Medical Center, Tel Aviv, Israel.




G. Vainer: Received advisory or consultant fees from Roche, Pfizer, Astra Zeneca and MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings